References
- Jam KK. Applied neurogenomics. Pharmacogenomics 2,143–153 (2001).
- Gurney M. A meeting of minds. Drug Discovery Today July 14, 6, 718–720 (2001).
- St. George-Hyslop PH. Molecular genetics of Alzheimer's disease. Biol. Psycklatry47, 200–209 (2000).
- Almkvist O, Jelic V, Amberla K et al Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement. Geriatr. Cogn. Disord 12,22–32 (2001).
- Aerssens J, Raeymaekers P, Lilienfeld S et al ApoE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12,69–77 (2001).
- Jam KK. An evaluation of memantine in the management of dementia. Exp. Opin. Invest. Drugs 9,1397–1406 (2000).
- Conner JM, Darracq MA, Roberts J, Tuszynski MH. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc. Natl Acad. Sci. USA 98, 1941–1946 (2001).
- Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol 48,567–579 (2000).
- Dominguez DI, De Strooper B, Annaert W Secretases as therapeutic targets for the treatment of Alzheimer's disease. Arnyloid8, 124–42 (2001).
- Jam KK. Neuroproteomics. Medlink Neurology, San Diego, California, (2001).